U Harmenberg1, M Lindskog2, G Sinclair3,4,5, M Stenman2, H Benmakhlouf6, P Wersäll1, P Johnstone7, M A Hatiboglu8, J Mayer-da-Silva9. 1. Department of Oncology-Pathology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden. 2. Department of Immunology, Genetics, and Pathology, Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden. 3. Department of Neurosurgery, Bezmialem Vakif University Medical School, Istanbul, Turkey. georges.sinclair@gmail.com. 4. Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden. georges.sinclair@gmail.com. 5. Department of Oncology, North Middlesex University Hospital NHS Trust, London, UK. georges.sinclair@gmail.com. 6. Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden. 7. Department of Oncology, Oxford University Hospitals NHS Trust, Oxford, UK. 8. Department of Neurosurgery, Bezmialem Vakif University Medical School, Istanbul, Turkey. 9. Centro Gamma Knife, CUF Infante Santo Hospital, Lisbon, Portugal.
Abstract
INTRODUCTION: The effects of single-fraction gamma knife radiosurgery (sf-GKRS) on patients with renal cell carcinoma (RCC) brain metastases (BM) in the era of targeted agents (TA) and immune checkpoint inhibitors (ICI) are insufficiently studied. METHODS AND MATERIALS: Clear cell metastatic RCC patients treated with sf-GKRS due to BM in 2005-2014 at three European centres were retrospectively analysed (n = 43). Median follow-up was 56 months. Ninety-five percent had prior nephrectomy, 53% synchronous metastasis and 86% extracranial disease at first sf-GKRS. Karnofsky performance status (KPS) ranged from 60 to 100%. Outcome measures were overall survival (OS), local control (LC) and adverse radiation effects (ARE). RESULTS: One hundred and ninety-four targets were irradiated. The median number of targets at first sf-GKRS was two. The median prescription dose was 22.0 Gy. Thirty-seven percent had repeated sf-GKRS. Eighty-eight percent received TA. LC rates at 12 and 18 months were 97% and 90%. Median OS from the first sf-GKRS was 15.7 months. Low serum albumin (HR for death 5.3), corticosteroid use pre-sf-GKRS (HR for death 5.8) and KPS < 80 (HR for death 9.1) were independently associated with worse OS. No further prognostic information was gleaned from MSKCC risk group, synchronous metastasis, age, number of BM or extracranial metastases. Other prognostic scores for BM radiosurgery, including DS-GPA, renal-GPA, LLV-SIR and CITV-SIR, again, did not add further prognostic value. ARE were seldom symptomatic and were associated with tumour volume, 10-Gy volume and pre-treatment perifocal oedema. ARE were less common among patients treated with TA within 1 month of sf-GKRS. CONCLUSIONS: We identified albumin, corticosteroid use and KPS as independent prognostic factors for sf-GKRS of clear cell RCC BM. Studies focusing on the prognostic significance of albumin in sf-GKRS are rare. Further studies with a larger number of patients are warranted to confirm the above analytical outcome. Also, in keeping with previous studies, our data showed optimal rates of local tumour control and limited toxicity post radiosurgery, rendering GKRS the tool of choice in the management of RCC BM.
INTRODUCTION: The effects of single-fraction gamma knife radiosurgery (sf-GKRS) on patients with renal cell carcinoma (RCC) brain metastases (BM) in the era of targeted agents (TA) and immune checkpoint inhibitors (ICI) are insufficiently studied. METHODS AND MATERIALS: Clear cell metastatic RCCpatients treated with sf-GKRS due to BM in 2005-2014 at three European centres were retrospectively analysed (n = 43). Median follow-up was 56 months. Ninety-five percent had prior nephrectomy, 53% synchronous metastasis and 86% extracranial disease at first sf-GKRS. Karnofsky performance status (KPS) ranged from 60 to 100%. Outcome measures were overall survival (OS), local control (LC) and adverse radiation effects (ARE). RESULTS: One hundred and ninety-four targets were irradiated. The median number of targets at first sf-GKRS was two. The median prescription dose was 22.0 Gy. Thirty-seven percent had repeated sf-GKRS. Eighty-eight percent received TA. LC rates at 12 and 18 months were 97% and 90%. Median OS from the first sf-GKRS was 15.7 months. Low serum albumin (HR for death 5.3), corticosteroid use pre-sf-GKRS (HR for death 5.8) and KPS < 80 (HR for death 9.1) were independently associated with worse OS. No further prognostic information was gleaned from MSKCC risk group, synchronous metastasis, age, number of BM or extracranial metastases. Other prognostic scores for BM radiosurgery, including DS-GPA, renal-GPA, LLV-SIR and CITV-SIR, again, did not add further prognostic value. ARE were seldom symptomatic and were associated with tumour volume, 10-Gy volume and pre-treatment perifocal oedema. ARE were less common among patients treated with TA within 1 month of sf-GKRS. CONCLUSIONS: We identified albumin, corticosteroid use and KPS as independent prognostic factors for sf-GKRS of clear cell RCC BM. Studies focusing on the prognostic significance of albumin in sf-GKRS are rare. Further studies with a larger number of patients are warranted to confirm the above analytical outcome. Also, in keeping with previous studies, our data showed optimal rates of local tumour control and limited toxicity post radiosurgery, rendering GKRS the tool of choice in the management of RCC BM.
Authors: Pedro C Barata; Prateek Mendiratta; Rupesh Kotecha; Dharmesh Gopalakrishnan; Aditya Juloori; Samuel T Chao; Vadim Koshkin; Moshe Ornstein; Timothy D Gilligan; Laura S Wood; Brian I Rini; Lilyana Angelov; Jorge A Garcia Journal: Clin Genitourin Cancer Date: 2018-08-17 Impact factor: 2.872
Authors: Lilyana Angelov; Alireza M Mohammadi; Elizabeth E Bennett; Mahmoud Abbassy; Paul Elson; Samuel T Chao; Joshua S Montgomery; Ghaith Habboub; Michael A Vogelbaum; John H Suh; Erin S Murphy; Manmeet S Ahluwalia; Sean J Nagel; Gene H Barnett Journal: J Neurosurg Date: 2017-09-22 Impact factor: 5.115
Authors: Se Young Choi; Sangjun Yoo; Dalsan You; In Gab Jeong; Cheryn Song; Bumsik Hong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim Journal: Clin Genitourin Cancer Date: 2017-05-10 Impact factor: 2.872
Authors: R M Auchter; J P Lamond; E Alexander; J M Buatti; R Chappell; W A Friedman; T J Kinsella; A B Levin; W R Noyes; C J Schultz; J S Loeffler; M P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 1996-04-01 Impact factor: 7.038
Authors: Linda Chen; Jacqueline Douglass; Lawrence Kleinberg; Xiaobu Ye; Ariel E Marciscano; Patrick M Forde; Julie Brahmer; Evan Lipson; William Sharfman; Hans Hammers; Jarushka Naidoo; Chetan Bettegowda; Michael Lim; Kristin J Redmond Journal: Int J Radiat Oncol Biol Phys Date: 2017-12-05 Impact factor: 7.038
Authors: David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran Journal: Lancet Date: 2004-05-22 Impact factor: 79.321
Authors: Sebastian Rubino; Daniel E Oliver; Nam D Tran; Michael A Vogelbaum; Peter A Forsyth; Hsiang-Hsuan Michael Yu; Kamran Ahmed; Arnold B Etame Journal: Front Oncol Date: 2022-03-02 Impact factor: 6.244